<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908257</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-127</org_study_id>
    <nct_id>NCT01908257</nct_id>
  </id_info>
  <brief_title>Lesinurad Interaction Study With Ranitidine</brief_title>
  <official_title>A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug-drug interaction study in healthy volunteers to evaluate the potential
      pharmacokinetic (PK) effects of ranitidine on lesinurad.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the potential effect of ranitidine on the pharmacokinetics of
      lesinurad. An earlier study demonstrated an effect on lesinurad PK in the presence of both
      calcium-containing and magnesium- and aluminum-containing antacids. The current study will
      assess whether raising gastric pH, without the presence of these cations, affects lesinurad
      PK and PD under the fasted state. If an impact is seen, then the optional second cohort will
      be conducted under the fed state.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of lesinurad from plasma and urine</measure>
    <time_frame>Days 1 and 6 (Sequence 1) or Days 2 and 7 (Sequence 2)</time_frame>
    <description>Profile in terms of Cmax, Tmax, AUC, CL/F, t1/2
Cmax: maximum concentration; Tmax: time to reach max plasma concentration; AUC: area under the concentration-time curve; CL/F: total body clearance corrected for bioavailability; t1/2: apparent terminal half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD profile of lesinurad from serum</measure>
    <time_frame>Days 1 and 6 (Sequence 1) or Days 2 and 7 (Sequence 2)</time_frame>
    <description>Profile in terms of serum urate concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1 fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Lesinurad 400 mg once daily (qd)
Day 5: Ranitidine 150 mg twice daily (bid)
Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.
Day 7: Ranitidine 150 mg (bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Ranitidine 150 mg (bid)
Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad
Day 3: Ranitidine 150 mg (bid)
Day 7: Lesinurad 400 mg (qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesinurad 400 mg</intervention_name>
    <arm_group_label>Sequence 1 fasted</arm_group_label>
    <arm_group_label>Sequence 2 fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranitidine 150 mg</intervention_name>
    <arm_group_label>Sequence 1 fasted</arm_group_label>
    <arm_group_label>Sequence 2 fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesinurad 400 mg + ranitidine 150 mg</intervention_name>
    <arm_group_label>Sequence 1 fasted</arm_group_label>
    <arm_group_label>Sequence 2 fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body weight ≥ 50 kg (110 lbs) and body mass index ≥ 18 and ≤ 30 kg/m2.

          -  Screening sUA value ≤ 7.0 mg/dL.

          -  free of any clinically significant disease that requires a physician's care and/or
             would interfere with study evaluations or procedures.

          -  Subject has no clinically relevant abnormalties in vital signs, ECG, physical
             examination or safety laboratory values per the Investigator's judgment.

        Exclusion Criteria:

          -  history or clinical manifestations of significant metabolic, hematological, pulmonary,
             cardiovascular, gastrointestinal, neurologic, hepatic renal,urological, or psychiatric
             disorders.

          -  history or suspicion of kidney stones.

          -  undergone major surgery within 3 months prior to Day 1.

          -  donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior
             to Day 1 or gave a plasma donation within 4 weeks prior to the Screening visit.

          -  inadequate venous access or unsuitable veins for repeated venipuncture.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Bradley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

